title: [Effects of the combination of angiotensin receptor blockers and thiazide diuretics on laboratory values (levels of serum potassium, sodium, and uric acid)].
abstract: The combination of angiotensin receptor blockers (ARB) and a thiazide diuretic (hereafter, ARB/diuretic) is expected to improve patient adherence and increase the therapeutic effects because of the lower number of pills that require to be administered. In addition, an ARB/diuretic combination alleviates hypokalemia that frequently develops in patients receiving thiazide diuretics. In this study, we used electronic medical records to investigate the laboratory values (serum levels of potassium, sodium, and uric acid) of 194 ambulatory and hospitalized patients at the Gifu Municipal Hospital who received ARB/diuretic combination therapy for the first time between February 2010 and September 2012. According to the grade of classification of low serum potassium and sodium levels, the serum potassium level in one patient was grade 3 and the serum sodium level in two patients was grade 3 after the initiation of ARB/diuretic combination therapy. After administration of ARB/diuretic combination therapy, two patients received potassium supplements because their serum potassium levels decreased below the reference value. Similarly, one patient received a sodium supplement because of a decrease in the sodium level below the reference value. Uric acid level increased above the reference value after administration of the ARB/diuretic combination therapy in one patient; thus, this patient received antihyperuricemic agents. Therefore, pharmacists must carefully monitor the serum levels of potassium, sodium, and uric acid, particularly in the first six months after the initiation of ARB/diuretic combination therapy.
authors.affiliation: Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Takahashi
authors.forename: Hitomi
authors.initials: H
authors.lastname: Teramachi
authors.forename: Tomoya
authors.initials: T
authors.lastname: Tachi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nagasawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Mizui
authors.forename: Chitoshi
authors.initials: C
authors.lastname: Goto
authors.forename: Teruo
authors.initials: T
authors.lastname: Tsuchiya
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood*; D012964:Sodium / Q000097:blood*; D049971:Thiazides / Q000009:adverse effects / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood*
chemical_list: D057911:Angiotensin Receptor Antagonists; D004338:Drug Combinations; D049971:Thiazides; D014527:Uric Acid; D012964:Sodium; D011188:Potassium